

**Amendments To The Claims:**

Please amend claims 12, 16, and 33, as set forth below in the Listing of Claims.

Please cancel claims 13, 14, and 15.

The current Listing of Claims replaces all prior listings.

**Listing of Claims:**

1-11. (Cancelled)

12. (Currently Amended) A method for introducing a differentiated CNS cell into a murine or primate comprising:

- (a) plating human CNS progenitor cells on a surface that permits proliferation, wherein the surface is a tissue culture plastic or a surface treated with fibronectin;
- (b) allowing the CNS progenitor cells to proliferate in serum-free medium;
- (c) transfecting the cells with DNA encoding a selectable marker and regulatable growth-promoting gene selected from the group consisting of SV40 large T antigen, v-myc, N-myc, c-myc, p53, polyoma large T antigen, Ela adenovirus and E7 protein of human papilloma virus;
- (d) passaging the transfected cells onto a substrate; and
- (e) adding serum-free growth medium containing one or more proliferation-enhancing factors to the transfected cells, wherein the proliferation-enhancing factors are selected from the group consisting of FGF-2, PDGF, EGF, medium conditioned by perpetualized adult rat hippocampal progenitor cells, and a combination thereof, thereby producing conditionally-immortalized human CNS progenitor cells[[, and]]; and
- (f) administering the CNS progenitor cells to the murine or primate; and
- (g) suppressing the production or activity of the growth-promoting gene, thereby inducing the CNS progenitor cells to differentiate into neurons and/or astrocytes.

Claims 13-15. (Cancelled)

16. (Currently Amended) The method of claim 15 12, wherein the subject murine or primate is afflicted with a pathological condition where neurons have degenerated.

17. (Previously Presented) The method of claim 16, wherein the pathological condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and traumatic head injury.

18-32. (Canceled)

33. (Currently Amended) The method of claim 12 ~~or 14~~, wherein the substrate is fibronectin, polyornithine, laminin, or a combination thereof.